FDA Cites Jabil Inc. in 2026-08-27 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
On August 27, 2026, the FDA's Center for Drug Evaluation and Research issued a warning letter to Jabil Inc. (CEO Michael Dastoor) regarding Current Good Manufacturing Practice violations at its Pharmaceutics International, Inc. subsidiary in Cockeysville, Maryland (FEI 3006503102), following an inspection conducted February 23–March 6, 2026. The FDA documented failures to thoroughly investigate sterility test failures and recurring fungal contamination in ISO 5 filling areas, including inadequate root cause analysis and corrective actions for multiple mold recoveries (Ustilago spermophora, Chaetomium globosum, Didymella glomerata, Mycosphaerella africana) between March 2024 and June 2025, resulting in adulterated drug products under the Federal Food, Drug, and Cosmetic Act.
Argus analysis
# FDA Warning Letter Analysis: Jabil Inc.
**Company and Findings**
Jabil Inc., a contract manufacturer of sterile injectable pharmaceuticals, received a warning letter from FDA's Center for Drug Evaluation and Research (CDER) on August 27, 2026, following an inspection of its Pharmaceutics International facility in Cockeysville, Maryland, conducted February 23 to March 6, 2026. The FDA determined that Jabil's drug products are adulterated because manufacturing methods, facilities, and controls fail to meet Current Good Manufacturing Practice (CGMP) standards. Primary concerns centered on inadequate investigation of sterility test failures and recurring fungal contamination in critical aseptic processing areas.
**Regulatory Citations**
The violations cited 21 CFR parts 210 and 211 (CGMP regulations for finished pharmaceuticals) and specifically 21 CFR 211.192, which requires thorough investigation of unexplained batch discrepancies or specification failures. These sections establish the foundation for drug manufacturing oversight, mandating scientifically rigorous root-cause analysis and corrective/preventive actions (CAPA). The warning letter documented multiple instances since 2023 where Jabil failed to investigate fungal recoveries comprehensively—including Chaetomium globosum, Didymella glomerata, and Mycosphaerella africana—and closed investigations without adequate CAPA implementation. Jabil also violated 21 CFR 211.22(d), concerning quality unit responsibilities and oversight procedures.
**Response Timeline and Industry Monitoring**
Jabil submitted an initial response to FDA Form 483 observations on March 27, 2026, which FDA deemed insufficient. The warning letter demands comprehensive independent assessments of investigation systems, CAPA programs, contamination hazards, and environmental monitoring protocols, with detailed remediation timelines. Peer compliance officers should monitor for Jabil's submission of these detailed assessments and any subsequent FDA inspections or enforcement actions, including potential product seizures if remediation proves inadequate.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Jabil Inc. MARCS-CMS 731037 — August 27, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE Reference #: 320-26-120 Product: Drugs Recipient: Recipient Name Mr. Michael Dastoor Recipient Title Chief Executive Officer and Director Jabil Inc. 10800 Roosevelt Blvd. N. St. Petersburg , FL 33716 United States (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 27, 2026 WARNING LETTER Reference number: 320-26-120 To Mr. Michael Dastoor: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products and facilities. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice including, without limitation, seizure and injunction. FDA Inspection Violations were observed and documented during an inspection of your drug manufacturing facility, Pharmaceutics International, Inc. (a Jabil Company), FDA Establishment Identifier (FEI) 3006503102, at 103 Beaver Court, Cockeysville, MD, from February 23 to March 6, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your March 27, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility. 1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). Your firm operates as a contract manufacturer of sterile injectables for (b)(4) . You failed to adequately investigate a sterility test failure as well as recurring mold recoveries in…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has Jabil Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Jabil Inc. as of 2026-09-01. Argus ingests new FDA enforcement records daily.
- What FDA violations was Jabil Inc. cited for?
- The FDA Warning Letter to Jabil Inc. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Jabil Inc.?
- FDA issued the letter (MARCS-CMS 731037) on 2026-08-27 and posted it publicly on fda.gov on 2026-09-01.
- Is the FDA warning letter to Jabil Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jabil-inc-731037-08272026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Jabil Inc. in 2026-08-27 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-jabil-inc-2026-08-27-cgmp
"FDA Cites Jabil Inc. in 2026-08-27 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-jabil-inc-2026-08-27-cgmp.
Argus HQ Research. "FDA Cites Jabil Inc. in 2026-08-27 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed September 2, 2026. https://argushq.ai/fda/warning-letter/fda-wl-jabil-inc-2026-08-27-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_jabil_inc_2026_08_27_cgmp_2026,
title = {FDA Cites Jabil Inc. in 2026-08-27 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-jabil-inc-2026-08-27-cgmp},
note = {Accessed: September 2, 2026}
}